n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Carcinoma, Hepatocellular in 21 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "NS398, a selective cyclooxygenase-2 inhibitor, and simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, both exert an anticancer effect on hepatocellular carcinoma cells, but the effect of co-administration of the two drugs remains unknown." | 7.80 | Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. ( Byun, KS; Hwang, JW; Hyun, JJ; Jung, SW; Kim, JH; Koo, JS; Lee, SJ; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Woo, SU; Yeon, JE; Yim, H; Yim, HJ, 2014) |
| "NS398, a selective cyclooxygenase-2 inhibitor, and simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, both exert an anticancer effect on hepatocellular carcinoma cells, but the effect of co-administration of the two drugs remains unknown." | 3.80 | Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. ( Byun, KS; Hwang, JW; Hyun, JJ; Jung, SW; Kim, JH; Koo, JS; Lee, SJ; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Woo, SU; Yeon, JE; Yim, H; Yim, HJ, 2014) |
| "NS-398 inhibited the growth of hepatoma cells by an amount dependent on the concentration and the time since treatment." | 1.35 | [Down-regulation of survivin in growth inhibition of hepatoma cells induced by a selective cyclooxygenase-2 inhibitor]. ( Kim, DW; Kim, EY; Kim, HJ; Kim, SB; Shin, HD; Shin, JE; Shin, KC; Song, IH; Yun, SY, 2008) |
| "In four tested human hepatoma cell lines, overexpression of COX-2 was confirmed in HepG2, HuH7, and Chang liver cells, but not in PLC/PRF/5 cells." | 1.32 | Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. ( Hasan, M; Hillebrand, DJ; Hu, KQ; McCracken, JD; Mineyama, Y; Yu, CH, 2003) |
| "Thirty-six HCC tissues, 15 hepatoma cell lines, 1 colorectal cell line (HT-29), and 1 fibroblast cell line (SV80) were included in the study." | 1.31 | Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. ( Bae, SH; Jung, ES; Kim, BK; Kim, BS; Kim, DG; Park, YM; Ryu, WS, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (80.95) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SJ | 1 |
| Hwang, JW | 1 |
| Yim, H | 1 |
| Yim, HJ | 1 |
| Woo, SU | 1 |
| Suh, SJ | 1 |
| Hyun, JJ | 1 |
| Jung, SW | 1 |
| Koo, JS | 1 |
| Kim, JH | 1 |
| Seo, YS | 1 |
| Yeon, JE | 1 |
| Lee, SW | 1 |
| Byun, KS | 1 |
| Um, SH | 1 |
| Li, Z | 1 |
| You, K | 1 |
| Li, J | 1 |
| Wang, Y | 2 |
| Xu, H | 1 |
| Gao, B | 1 |
| Wang, J | 1 |
| Jang, JW | 1 |
| Song, IH | 1 |
| Kim, DW | 1 |
| Shin, KC | 1 |
| Shin, HD | 1 |
| Yun, SY | 1 |
| Kim, SB | 1 |
| Shin, JE | 1 |
| Kim, HJ | 1 |
| Kim, EY | 1 |
| Gong, W | 1 |
| Zhang, JL | 1 |
| Yan, XJ | 1 |
| Zhou, Q | 1 |
| Wang, ZY | 1 |
| Yi, TN | 1 |
| Lee, NO | 1 |
| Park, JW | 2 |
| Lee, JA | 2 |
| Shim, JH | 1 |
| Kong, SY | 1 |
| Kim, KT | 1 |
| Lee, YS | 1 |
| Cheng, J | 1 |
| Imanishi, H | 1 |
| Amuro, Y | 1 |
| Hada, T | 1 |
| Tabernero, A | 1 |
| Schneider, F | 1 |
| Potenza, MA | 1 |
| Randriamboavonjy, V | 1 |
| Chasserot, S | 1 |
| Wolf, P | 1 |
| Mitolo-Chieppa, D | 1 |
| Stoclet, JC | 1 |
| Andriantsitohaina, R | 1 |
| Hu, KQ | 1 |
| Yu, CH | 1 |
| Mineyama, Y | 1 |
| McCracken, JD | 1 |
| Hillebrand, DJ | 1 |
| Hasan, M | 1 |
| Cheng, AS | 1 |
| Chan, HL | 1 |
| Leung, WK | 1 |
| Wong, N | 1 |
| Johnson, PJ | 1 |
| Sung, JJ | 1 |
| Schmidt, CM | 2 |
| Wiesenauer, C | 1 |
| Park, MK | 1 |
| Hwang, SY | 1 |
| Kim, JO | 1 |
| Kwack, MH | 1 |
| Kim, JC | 1 |
| Kim, MK | 1 |
| Sung, YK | 1 |
| Huang, DS | 1 |
| Shen, KZ | 1 |
| Wei, JF | 1 |
| Liang, TB | 1 |
| Zheng, SS | 1 |
| Xie, HY | 1 |
| Zhang, LY | 1 |
| Wang, X | 1 |
| Zhang, YC | 1 |
| Fu, SJ | 1 |
| Ma, L | 1 |
| Park, JE | 1 |
| Lee, CW | 1 |
| Kim, CM | 1 |
| Ralstin, MC | 1 |
| Gage, EA | 1 |
| Yip-Schneider, MT | 1 |
| Klein, PJ | 1 |
| Wiebke, EA | 1 |
| Nakamoto, N | 1 |
| Higuchi, H | 1 |
| Kanamori, H | 1 |
| Kurita, S | 1 |
| Tada, S | 1 |
| Takaishi, H | 1 |
| Toda, K | 1 |
| Yamada, T | 1 |
| Kumagai, N | 1 |
| Saito, H | 1 |
| Hibi, T | 1 |
| Baek, JY | 1 |
| Hur, W | 1 |
| Wang, JS | 1 |
| Bae, SH | 2 |
| Yoon, SK | 1 |
| Li, S | 1 |
| Tong, Q | 1 |
| Zhang, W | 1 |
| Wang, Q | 1 |
| Chen, Z | 1 |
| Wu, Q | 1 |
| Jung, ES | 1 |
| Park, YM | 1 |
| Kim, BS | 1 |
| Kim, BK | 1 |
| Kim, DG | 1 |
| Ryu, WS | 1 |
| Abiru, S | 1 |
| Nakao, K | 1 |
| Ichikawa, T | 1 |
| Migita, K | 1 |
| Shigeno, M | 1 |
| Sakamoto, M | 1 |
| Ishikawa, H | 1 |
| Hamasaki, K | 1 |
| Nakata, K | 1 |
| Eguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; | 2014 |
Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Centella; Cyclooxygenase 2; Di | 2016 |
[Anti-tumor mechanisms and regulation of survivin by selective cyclooxygenase-2 inhibitor].
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2008 |
[Down-regulation of survivin in growth inhibition of hepatoma cells induced by a selective cyclooxygenase-2 inhibitor].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; G1 Pha | 2008 |
Lipopolysaccharide initiates a bypass feedback loop of epidermal growth factor receptor signaling by HPS70-induced COX-2 in H22 hepatocarcinoma cells.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase | 2011 |
Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2.
Topics: Carcinoma, Hepatocellular; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Cyclooxygenase 2 I | 2012 |
NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.
Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycl | 2002 |
Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.
Topics: Adult; Arteries; Blotting, Western; Carcinoma, Hepatocellular; Case-Control Studies; Cyclooxygenase | 2003 |
Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bromodeoxyuridine; Carcinoma, Hepatocellular; Cell Cycle | 2003 |
Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Topics: Annexin A5; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cell | 2003 |
Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
Topics: Adenocarcinoma; Apoptosis; Butadienes; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Li | 2003 |
NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspases; | 2004 |
Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.
Topics: Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Cy | 2005 |
[Effects of selective cyclooxygenase-2 inhibitor NS-398 on proliferation and cell cycle progression of hepatocarcinoma cells].
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Humans; Live | 2005 |
Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclo | 2006 |
Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Pro | 2006 |
Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; | 2006 |
Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2007 |
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Topics: Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; | 2008 |
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Cyclooxygen | 2001 |
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase 2; Cyclo | 2002 |